at best,they will need add'l trial
which should bring them to 50th or less untill it's completion
in the industry due to possible delisting of uralkali and weak performance of k+s,even though the last one is trying to make impression that business is good
either one would be good for pot
would be nice to see some net profit-it took Amazon decade and a half,and they still,probably,hiding some of their losses,considering their numerous collaborations.
Is US marketplace-this where 3 so-called analysts would give you 4 different opinions.
Dream job-just talking and carrying no responsibility.
Let me give you my advice:sell everything.
Botox is almost finished,considering rising competition and complications from multi usage.
This merger will be nightmare for Pfizer shareholders,even Irish tax haven will not save them.
he is not any different from bunch of other POS
green Buck is the only idol in this wonderland
here is the future of this company:after some of their high risk R&D programs will fail and pps decline 30%(also to market correction for various reasons),someone big will swallow it and cut another 20% of workforce
p.s.short term US market sentiment-sell everything
it is just desire to see pps of this gem higher-no insights,my little Russian pal
42 today,43 tmrw,48 by next week end and 52 after earnings